• Privacy policy
  • T&C’s
  • About Us
    • FAQ
    • Meet the Team
  • Contact us
  • Guest Content
TLE ONLINE SHOP!
  • TLE
  • News
  • Politics
  • Business
  • Sport
  • Opinion
  • Elevenses
  • Entertainment
    • All Entertainment
    • Film
    • Lifestyle
      • Horoscopes
    • Lottery Results
      • Lotto
      • Thunderball
      • Set For Life
      • EuroMillions
  • Food
    • All Food
    • Recipes
  • Property
  • Travel
  • Tech/Auto
  • JOBS
No Result
View All Result
The London Economic
SUPPORT THE LONDON ECONOMIC
NEWSLETTER
  • TLE
  • News
  • Politics
  • Business
  • Sport
  • Opinion
  • Elevenses
  • Entertainment
    • All Entertainment
    • Film
    • Lifestyle
      • Horoscopes
    • Lottery Results
      • Lotto
      • Thunderball
      • Set For Life
      • EuroMillions
  • Food
    • All Food
    • Recipes
  • Property
  • Travel
  • Tech/Auto
  • JOBS
No Result
View All Result
The London Economic
No Result
View All Result
Home Lifestyle Health

Cure for Parkinson’s disease could be on the horizon

It offers hope of the first drug that treats the cause of the devastating neurodegenerative illness.

Jim Leffman by Jim Leffman
2019-06-06 11:29
in Health, Lifestyle
FacebookTwitterLinkedinEmailWhatsapp

A cure for Parkinson’s disease could be on the horizon after scientists stopped symptoms in mice.

The revolutionary gene therapy destroys a toxic protein found in the brains of patients, a study found.

It offers hope of the first drug that treats the cause of the devastating neurodegenerative illness and might even have applications in some forms of dementia.

The poisonous chemical, called alpha synuclein, also clumps together in the grey matter of some dementia sufferers.

Senior author Professor Hideki Mochizuki, a neurologist at Osaka University, Japan, said: “We expect in the future, this method will be used to not only successfully treat Parkinson’s, but also dementia caused by α-synuclein accumulation.”

Parkinson’s affects 128,000 people in the UK. As well as damaging movement it affects the senses, memory and mood.

Blocking the accumulation of α-synuclein in the brain prevented its development in the lab rodents. This was done with a simple injection into their spinal canal.

Lead author Dr Takuya Uehara, a member of Prof Mochizuki’s lab, explained: “Although there are drugs that treat the symptoms associated with PD, there is no fundamental treatment to control the onset and progression of the disease.

“Therefore, we looked at ways to prevent the expression of α-synuclein and effectively eliminate the physiological cause of Parkinson’s.”

RelatedPosts

Lucky Numbers and Horoscopes for today 26 January 2023

Types of Personal Loans and When It’s a Good Idea to Get One According to Your Needs

Why Is It A Great Idea To Invest In Life Insurance?

Lucky Numbers and Horoscopes for today 25 January 2023

One in ten cases of Parkinson’s are hereditary. The vast majority are sporadic, meaning they occur at random with no family link. The a-synuclein molecule plays a major part in both forms.

The researchers say the findings published in Scientific Report provide “a ray of hope” for the millions of patients worldwide.

Although more common in the over 60s it can strike at any age, with 10 to 20 percent of patients diagnosed before they reach 50 and about half of those under 40.

And while not fatal in and of itself, the progressive degeneration often causes secondary effects that lead to death.

The exact cause is still a mystery, but it is believed both genetics and the environment are involved.

All patients show a loss of neurons in the brain that produce dopamine, a chemical that controls movement, and increased levels of α-synuclein.

These accumulate in Lewy bodies, molecules that develop inside nerve cells and are a pathological feature of both familial and sporadic Parkinson’s – as well as some types of dementia.

Dementia with Lewy bodies is the third most common cause of dementia, affecting about 100,000 people in the UK.

People with the disease experience distressing symptoms such as hallucinations, problems with movement similar to Parkinson’s and ‘cognitive fluctuations’ – variations in alertness, attention and thinking skills.

So the team designed short fragments of DNA that are mirror images of sections of the α-synuclein gene.

These were were stabilised using a chemistry technique called ‘amido-bridging’ that connects atoms.

The resulting pieces, called ASOs (amido-bridged nucleic acid-modified antisense oligonucleotides), bind to matching bits of DNA known as micro RNA (mRNA).

This prevented it from being turned into α-synuclein. After screening 50 different ASOs, the researchers settled on one that slashed the protein levels by 81 percent.

Co lead author Dr Chi-Jing Choong said: “When we tested the ASO in a mouse model of Parkinson’s disease, we found it was delivered to the brain without the need for chemical carriers.

“Further testing showed the ASO effectively decreased α-synuclein production in the mice and significantly reduced the severity of disease symptoms within 27 days of administration.”

The mice had been genetically engineered to develop a rodent form of Parkinson’s.

After the therapy they performed better in a series of tests devised to measure their motor function and control – such as walking on beams and wires and gnawing at pasta.

In Parkinson’s, toxic proteins build up in the brain to kill nerves, particularly those linked with movement.

It affects one million people in the US – and up to 10 milllion worldwide – causing muscle stiffness, slow movement, tremors, sleep disturbance, chronic fatigue, an impaired quality of life and severe disability.

Celebrity sufferers include Michael J Fox, Billy Connolly and Sweet Caroline singer Neil Diamond. It claimed the life of boxer Muhammad Ali.

Added Prof Mochizuki: “Our results showed gene therapy using α-synuclein-targeting ASOs is a promising strategy for the control and prevention of Parkinson’s disease.”

Please login to join discussion

Subscribe to our Newsletter

View our  Privacy Policy and Terms & Conditions

Trending on TLE

  • All
  • trending
Abdollah

‘Rescue us’: Afghan teacher begs UK to help him escape Taliban

CHOMSKY: “If Corbyn had been elected, Britain would be pursuing a much more sane course”

What If We Got Rid Of Prisons?

More from TLE

Downing Street held TWO raucous parties night before Prince Philip’s funeral

Britain First member issues “official warning” to people turning up at Jacob Rees-Mogg’s house

Buckingham Palace announces Donald Trump state visit in June, protests already planned

‘It’s desperate’: Producers ship meat to EU as butcher shortage bites

Gossip – Spurs & Chelsea men to Itlay?

Revealed: The science behind the common cold

‘Pig-headedness of British Airways’ blamed as BA workers to strike during school holidays

Biden pulls ahead in Pennsylvania, in touching distance of victory

VIDEO – Shocking Drone Footage of Syrian City of Homs

Michael Gove says ‘Christian forgiveness’ needed over Partygate

JOBS

FIND MORE JOBS

About Us

TheLondonEconomic.com – Open, accessible and accountable news, sport, culture and lifestyle.

Read more

Contact

Editorial enquiries, please contact: [email protected]

Commercial enquiries, please contact: advert[email protected]

Address

The London Economic Newspaper Limited t/a TLE
Company number 09221879
International House,
24 Holborn Viaduct,
London EC1A 2BN,
United Kingdom

SUPPORT

We do not charge or put articles behind a paywall. If you can, please show your appreciation for our free content by donating whatever you think is fair to help keep TLE growing and support real, independent, investigative journalism.

DONATE & SUPPORT

© 2019 thelondoneconomic.com - TLE, International House, 24 Holborn Viaduct, London EC1A 2BN. All Rights Reserved.




No Result
View All Result
  • Home
  • News
  • Politics
  • Business
  • Sport
  • Entertainment
  • Lifestyle
  • Food
  • Travel
  • JOBS
  • More…
    • Elevenses
    • Opinion
    • Property
    • Tech & Auto
  • About Us
    • Meet the Team
    • Privacy policy
  • Contact us

© 2019 thelondoneconomic.com - TLE, International House, 24 Holborn Viaduct, London EC1A 2BN. All Rights Reserved.